Randox News

Stroke detection with Randox Biochips

Randox Biochip Array Technology May Help with Stroke DetectionRapid patient profiling is now available with Randox Biochip Array Technology.  The system can analyse up to seven parameters simultaneously in a single patient sample. The new cerebral array utilises markers that could aid rapid diagnosis of various nervous system disorders such as stroke.

Randox has developed two instruments for analysis of biochips, the fully automated Evidence and the semi-automated Investigator analyser.

The new cerebral biochip array panel allows measurement of analytes associated with nervous system dysfunction, for example stroke, cerebrovascular disease, transient ischemic attack, and head injury.

Rapid assessment is critical for accurate diagnosis and to implement appropriate treatment plans. The Randox cerebral array has been validated for use with serum, plasma and cerebrospinal fluid. Only 25ul of sample is required for quantitative determination of seven analytes concurrently.

There are two cerebral array panels currently available from Randox. The first measures four analytes and includes heart type fatty acid binding protein which recently has been shown to be a very early marker for stroke detection with levels associated with the severity of the event. The second cerebral array measures seven parameters simultaneously. The analysis of several cerebrovascular disease markers gives a more comprehensive patient profile and could enhance the accuracy of the diagnostic result.

Implementation of Biochip Array Technology can save your laboratory valuable time and money and ultimately provide the clinician with more information on patient status.


About Randox

Headquartered in the United Kingdom, Randox Laboratories Ltd. is a market leader within the in vitro diagnostics industry, manufacturing high quality diagnostic products for laboratories worldwide. Our extensive product portfolio offers complete solutions within the fields of clinical chemistry, cardiology, forensic toxicology, veterinary, pharma services, drug residues, life sciences, oncology, molecular diagnostics and internal and external quality control. Our goal is to ‘revolutionise healthcare through continuously improving diagnostic solutions.’ We continue to achieve this year after year due to our commitment and significant re-investment in Research and Development. Our innovative approach to diagnostics allows us to develop revolutionary products, specifically designed to provide more efficient, higher quality and reliable results, ensuring patients receive the right diagnosis at the right time.

Leave a Reply

Your email address will not be published. Required fields are marked *